CKPT (Checkpoint Therapeutics) Pangali Forward P/E
A stable geopolitical backdrop for biomedicine has driven share price growth, which is supported by Checkpoint Therapeutics (CKPT) forward P/E valuation, where the metric stands at 3.80. This positive momentum is based on Cosibelimab patents for high margins and a partnership with TG Therapeutics in therapy development. Such fundamental factors create a solid foundation for future cash flow and successful clinical trials.
Ringkesan rincian data analitis Checkpoint Therapeutics Inc (CKPT)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Checkpoint Therapeutics|CKPT - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Checkpoint Therapeutics|CKPT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Checkpoint Therapeutics Inc.|CKPT - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Checkpoint Therapeutics|Rasio cepet checkpointtx.com
- rincian asil keuangan lan kelipatan valuasi:
CKPT - Penghasilan resik|Bathi sing dikarepake Checkpoint Therapeutics|CKPT - Pangali P/E|Rega marang bathi mangsa ngarep Checkpoint Therapeutics, Inc|CKPT - Rasio kapitalisasi marang bathi lan wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Checkpoint Therapeutics Inc.|CKPT - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Checkpoint Therapeutics|CKPT - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan checkpointtx.com|CKPT - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Checkpoint Therapeutics
Analisis fundamental perusahaan:Checkpoint Therapeutics, Inc.
Investors are evaluating the operating model of Checkpoint Therapeutics (CKPT) using a forward P/E ratio, which compares current market capitalization to expected earnings per share. By analyzing the company's forward P/E, one can determine the extent of the premium paid for cosibelimab's potential prior to FDA approval, where sharp deviations in the chart would indicate either unjustified optimism or the risk of business degradation.
Pesaing langsung
Prakiraan rega marang bathi ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (RevMed)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Therapeutics (BCAX) - Rega marang bathi mangsa ngarep|Personalis Inc - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Corp DCTH|Pangali Forward P/E YMAB|Prakiraan rega marang bathi aurabiosciences.com AURA|Pangali Forward P/E CADL (Candel Therapeutics, Inc.)|Pangali mangsa ngarep rega marang bathi ARAY|SELLAS Life Sciences Group Inc. - Pangali Forward P/E|Rasio prakiraan rega marang bathi Actuate Therapeutics Inc|CTOR: Pangali Forward P/E|Prakiraan rega marang bathi TuHURA Biosciences|Rega marang bathi mangsa ngarep Protara Therapeutics, Inc.|Pangali Forward P/E Fate Therapeutics Inc|Rega marang bathi mangsa ngarep Aadi Bioscience Inc (WHWK)|TCRX: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBiotech Inc (XBIT) - Rasio prakiraan rega marang bathi|CEL-SCI Corp - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi OS Therapies Inc. OSTX|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep ARTV|Prakiraan rega marang bathi ANL|VERU (verupharma.com) - Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi TPST (Tempest Therapeutics, Inc.)|XLO (xiliotx.com) - Pangali mangsa ngarep rega marang bathi|Renovaro - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep MURA (Mural Oncology PLC)|Kairos Pharma Inc - Pangali Forward P/E|Pangali mangsa ngarep rega marang bathi OKUR (OnKure Therapeutics Inc)|GDTC: Pangali Forward P/E|Rasio prakiraan rega marang bathi Curis (CRIS)|Rega marang bathi mangsa ngarep Apollomics Inc.|THAR: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E ADVB|Pangali Forward P/E genprex.com (GNPX)|Rega marang bathi mangsa ngarep Calidi Biotherapeutics, Inc. CLDI|SBFM (Sunshine Biopharma Inc.) - Rasio rega marang bathi sing dikarepake|Xenetic Bio - Pangali Forward P/E|Rasio prakiraan rega marang bathi Salarius Pharma|PPBT (Purple Biotech) - Prakiraan rega marang bathi|American Oncology Network, Inc. (AONC) - Pangali Forward P/E|Prakiraan rega marang bathi BGNE|ELEV (elevationoncology.com) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E ICAD|Kapitalisasi marang proyeksi bathi ikenaoncology.com|Pangali Forward P/E NTBL (Notable Labs, Ltd.)|VIRX - Prakiraan rega marang bathi|MOR - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi NAYA Biosciences Inc NAYA|AAPGV: Pangali Forward P/E
